Two 'atypical' antipsychotic drugs, olanzapine (Zyprexa - Lilly) and sertindole (Serdolect - Lundbeck), were introduced in late 1996. Both drugs are licensed for the treatment of patients with schizophrenia, which affects nearly 1% of people within their lifetime.1 Here we discuss whether olanzapine and sertindole have any advantages over conventional antipsychotic drugs2 or the other, older, 'atypical' antipsychotics, risperidone3 and clozapine.4
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.